Sebastian Koschade
Overview
Explore the profile of Sebastian Koschade including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
20
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ballo O, Eladly F, Koschade S, Buttner S, Stratmann J, Brunnberg U, et al.
Ann Hematol
. 2021 Jul;
100(10):2603-2611.
PMID: 34304288
Treatment-related complications contribute substantially to morbidity and mortality in acute myeloid leukemia (AML) patients undergoing induction chemotherapy. Although AML patients are susceptible to fluid overload (FO) (e.g., in the context...
2.
Stratmann J, Lacko R, Ballo O, Shaid S, Gleiber W, Vehreschild M, et al.
PLoS One
. 2020 Nov;
15(11):e0242544.
PMID: 33237921
Objectives: Multidrug-resistant organisms (MDRO) are considered an emerging threat worldwide. Data covering the clinical impact of MDRO colonization in patients with solid malignancies, however, is widely missing. We sought to...
3.
Sebastian M, Koschade S, Stratmann J
J Thorac Oncol
. 2019 Nov;
14(11):1878-1880.
PMID: 31668313
No abstract available.
4.
Stratmann J, van Kann E, Rummelt C, Koschade S, Rollig C, Lubbert M, et al.
Leuk Res
. 2019 Aug;
85:106192.
PMID: 31445469
Relapsed or refractory (R/R) disease remains challenging in acute myeloid leukemia (AML), especially in elderly patients not considered eligible for intensive treatment options. We retrospectively evaluated the safety and efficacy...
5.
Stratmann J, Becker von Rose A, Koschade S, Wendelin K, Kohler F, Heinsch M, et al.
Ann Hematol
. 2019 Jan;
98(3):647-656.
PMID: 30613837
The 2016 revised World Health Organization (WHO) classification of lymphoid neoplasms included the category of high-grade B cell lymphomas (HGBLs) with combined MYC and BCL2 and/or BCL6 rearrangements (double-hit, DH)....
6.
Engl T, Rutz J, Maxeiner S, Fanguen S, Juengel E, Koschade S, et al.
Oncotarget
. 2018 May;
9(27):18747-18759.
PMID: 29721158
The mechanistic target of the rapamycin (mTOR) inhibitor, temsirolimus, has significantly improved the outcome of patients with renal cell carcinoma (RCC). However, development of temsirolimus-resistance limits its effect and metastatic...